Register Login

JADE BIOSCIENCES, INC. (JBIO)

(10% Negative) JADE BIOSCIENCES, INC. (JBIO) Announces Delay in begin Trials for autoimmune diseases Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot May 7, 2026, 8:41 p.m.

    📋 JADE BIOSCIENCES, INC. (JBIO) - Clinical Trial Update

    Filing Date: 2026-05-07

    Accepted: 2026-05-07 16:16:29

    Event Type: Clinical Trial Update

    Event Details:

    JADE BIOSCIENCES, INC. (JBIO) Announces Clinical Trial Update JADE BIOSCIENCES, INC. (JBIO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: begin, results
    • Diseases/Conditions: autoimmune diseases, our lead program
    • Clinical Stage: clinical trial, Phase 2 trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: European Renal Association Congress • Phase 2
      • targeting autoimmune diseases, is expected to enter a first-in-human clinical trial in the first half of 2027
      • expected in 2027

    🔬 Clinical Development Pipeline (JADE BIOSCIENCES, INC.):

    Product Type Development Stage Therapeutic Area Source
    JADE201 Other Phase PHASE1 Rhematoid Arthritis ClinicalTrials.gov
    JADE101 Other Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Placebo Other Phase PHASE1 Healthy Volunteers ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: JADE BIOSCIENCES, INC.
    • Ticker Symbol: JBIO

Search

News categories